Published in Blood Weekly, March 30th, 2000
"Certain groups of thrombocytopenic adults respond favorably to the administration of recombinant thrombopoietin or to PEG-rHuMGDF, a recombinant human polypeptide that contains the receptor-binding N-terminal domain of thrombopoietin," according to M.C. Sola and colleagues, University of California, Davis. It is unknown whether this treatment is safe for human infants, however.
Sola et al. performed a study to investigate the effects of PEG-rHuMGDF on newborn rhesus monkeys ("Pharmacokinetics,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.